«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《现代肿瘤医学》[ISSN:1672-4992/CN:61-1415/R]

期数:

2019年13期

页码:

2354-2359

栏目:

论著（消化·泌尿系肿瘤）

出版日期:

2019-05-31

文章信息/Info

Title:

Comparison on the efficacy and safety of mFOLFOX6 method and SOX method in the treatment of liver metastasis of gallbladder carcinoma

作者:

雒小佳¹; 魏红侠¹; 胡海峰²

1.西安交通大学第一附属医院放疗科，陕西 西安 710061; 2.延安大学附属医院肿瘤科，陕西 延安 716000

Author(s):

Luo Xiaojia¹; Wei Hongxia¹; Hu Haifeng²

1.Department of Radiotherapy，the First Affiliated Hospital of Xi'an Jiaotong University，Shaanxi Xi'an 710061，China；2.Department of Oncology，Affiliated Hospital of Yan'an University，Shaanxi Yan'an 716000，China.

关键词:

SOX方案; mFOLFOX6方案; 胆囊癌肝转移

Keywords:

SOX method; mFOLFOX6 method; liver metastasis of gallbladder carcinoma

分类号:

R735.8

DOI:

10.3969/j.issn.1672-4992.2019.13.028

文献标识码:

A

摘要:

目的：比较mFOLFOX6方案（奥沙利铂+亚叶酸钙+5-氟尿嘧啶）与SOX方案（奥沙利铂+替吉奥）化疗治疗不可切除的胆囊癌肝转移的临床疗效及安全性。方法：将我院收治的208例不可切除的胆囊癌肝转移患者随机分为观察组及对照组，每组104例。对照组均给予mFOLFOX6方案进行化疗，观察组则均给予SOX方案进行化疗，两组患者均连续治疗4个疗程。治疗期间，观察两组患者毒副反应发生情况，主要观察指标包括肝毒性、神经毒性、心脏毒性、白细胞计数降低情况、胃肠道反应及血小板降低情况等。治疗后，观察两组患者临床疗效。治疗前后，对两组患者白蛋白（ALB）、总胆红素（TBIL）、天门冬氨酸氨基转移酶（AST）及谷丙转氨酶（ALT）等肝功能指标含量进行检测。治疗后，对两组患者进行为期2年的随访，观察两组患者1年生存率、2年生存率、无疾病进展生存时间（PFS）和总生存时间（OS）。结果：治疗后，观察组客观缓解率（ORR）及临床获益率（CBR）均明显高于对照组（P<0.05）。治疗期间，观察组肝毒性、神经毒性、心脏毒性、白细胞计数降低、胃肠道反应及血小板降低等毒副反应的发生率均明显低于对照组（P<0.05）。治疗后，观察组ALB、TBIL、AST及ALT等肝功能指标的改善程度均显著优于对照组（P<0.05）。治疗后，观察组1年生存率、2年生存率、PFS及OS均显著高于对照组（P<0.05）。结论：SOX方案化疗治疗胆囊癌肝转移患者的疗效优于mFOLFOX6方案，且安全性更佳。

Abstract:

Objective：To compare the efficacy and safety of mFOLFOX6 method and SOX method in the treatment of liver metastasis of gallbladder carcinoma.Methods：208 patients with liver metastasis of gallbladder carcinoma in our hospital were selected as the participants and randomly divided observation group（104 cases) and control group（104 cases).The control group was treated by mFOLFOX6 method，while the observation group was treated by SOX method.During the treatment，toxicity effects in the two groups were observed，including liver toxicity，neurotoxicity，cardiac toxicity，decreased white blood cell count，gastrointestinal reaction and thrombocytopenia.After treatment，the curative effects were evaluated.Before and after treatment，the levels of liver function in the two groups were evaluated，mainly containing albumin（ALB)，total bilirubin（TBIL)，aspartate aminotransferase（AST) and alanine transaminase alt（ALT).After treatment，2 years-followed up in the two groups were observed，and 1-year survival rate，2-year survival rate，disease-free progression survival time（PFS) and total survival time（OS) were observed.Results：After treatment，the ORR and CBR in the observation group were significantly higher than the control group（P<0.05).During the treatment，the rates of liver toxicity，neurotoxicity，cardiac toxicity，decreased white blood cell count，gastrointestinal reaction and thrombocytopenia in the observation group were significantly lower than the control group（P<0.05).After treatment，the liver function index（ALB，TBIL，AST and ALT) were significantly promoted in the observation group than those of the control group（P<0.05）.After treatment，the 1-year survival rate，2-year survival rate，PFS and OS in the observation group were significantly higher than the control group（P<0.05).Conclusion：SOX method has a better effect and safety for therapy in the treatment of liver metastasis of gallbladder carcinoma than the mFOLFOX6 method.

参考文献/References

[1]Kakaei F，Beheshtirouy S，Nejatollahi SM，et al.Surgical treatment of gallbladder carcinoma：A critical review［J］.Updates Surg，2015，67(4)：339-351.
[2]Emmett CD，Barrett P，Gilliam AD，et al.Routine versus selective histological examination after cholecystectomy to exclude incidentalgallbladder carcinoma［J］.Ann R Coll Surg Engl，2015，97(7)：526-529.
[3]Xu JQ，Chen C，Song HW，et al.Analysis of relevant factors in pathogenesis of gallbladder cancer［J］.Chinese Journal of General Surgery，2015，24(2)：190-194.［徐建庆，陈晨，宋虎伟，等.胆囊癌发病相关危险因素分析［J］.中国普通外科杂志，2015，24(2)：190-194.］
[4]Song XL，Liang HB，Wang WM，et al.Surgical treatment and clinical prognosis of gallbladder cancer［J］.Journal of Hepatopancreatobiliary Surgery，2016，28(6)：465-468.［宋晓玲，梁海滨，王卫民，等.胆囊癌外科治疗与临床预后分析［J］.肝胆胰外科杂志，2016，28(6)：465-468.］
[5]Zhang Heng，Bai Yuxian，Zhang Wenjie，et al.Advances in treatment of advanced stage gallbladder carcinoma［J］.Modern Oncology，2015，23(19)：2865-2868.［张恒，白玉贤，张文杰，等.进展期胆囊癌的治疗进展［J］.现代肿瘤医学，2015，23(19)：2865-2868.］
[6]Ministry of Health of the People's Ruepblic of China.Criteria of diagnosis and treatment for common malignant tumors［M］.Beijing：Beijing Union Medical University Press,1996：16-19.［中华人民共和国卫生部.中国常见恶性肿瘤诊治规范［M］.北京：北京医科大学中国协和医科大学联合出版社，1996：16-19.］
[7]Chen ZW，Liao ML.Evaluation of tumor response with RECIST criteria［J］.China Tumor，2004，13(10)：616-618.［陈智伟，廖美琳.RECIST标准在肿瘤治疗疗效评价中的应用［J］.中国肿瘤，2004，13(10)：616-618.］
[8]Li B，Liu C，Jiang XQ，et al.Guideline for the diagnosis and therapy of gallbladder carcinoma(2016)［J］.Journal of Clinical Hepatology,2017，22(4)：721-728.［李斌，刘辰，姜小清，等.胆囊癌规范化诊治专家共识(2016)［J］.临床肝胆病杂志，2017，22(4)：721-728.］
[9]Li RF，Ye JW，Qi L，et al.The expression and clinical significance of hypoxia-induced factor-1 α in gallbladder carcinoma tissues and its role on metformin-suppressed metastasis in GBC-SD cells［J］.Chinese Journal of Hepatobiliary Surgery，2017，23(6)：383-388.［李仁锋，叶健文，齐蕾，等.低氧诱导因子-1α在胆囊癌组织中的表达及其在二甲双胍抑制胆囊癌转移中的作用［J］.中华肝胆外科杂志，2017，23(6)：383-388.］
[10]Peng CH，Zhan Q，Chen MM.Characteristics of gallbladder carcinoma invasion and metastasis and indication of lymph node dissection［J］.Chinese Journal of Practical Surgery，2016，36(10)：1045-1048.［彭承宏，詹茜，陈梦闽.胆囊癌侵袭转移特点及淋巴结清扫指征与技巧［J］.中国实用外科杂志，2016，36(10)：1045-1048.］
[11]Song HW，Shen HX，Chen C，et al.Gallbladder cancer：A comprehensive review on basic research［J］.Chinese Journal of Hepatobiliary Surgery，2015，21(8)：574-576.［宋虎伟，慎浩鑫，陈晨，等.胆囊癌相关基础研究进展［J］.中华肝胆外科杂志，2015，21(8)：574-576.］
[12]Liu DB，Xu DH.Advances in laparoscopic radical cholecystectomy［J］.Chinese Journal of Hepatic Surgery，2017，6(2)：77-80.［刘东斌，徐大华.腹腔镜胆囊癌根治术的研究进展［J］.中华肝脏外科手术学电子杂志，2017，6(2)：77-80.］
[13]Cong LL，Liu DC，Wang L，et al.The progress research on the mechanism of lymphatic metastasis in gallbladder cancer［J］.Chinese Journal of Experimental Surgery，2017，34(3)：537-540.［丛龙龙，刘德春，王林，等.胆囊癌淋巴转移机制研究进展［J］.中华实验外科杂志，2017，34(3)：537-540.］
[14]Yang JZ.Clinical efficacy of gemcitabine combined with tegafur in the chemotherapy of advanced gall bladder cancer［J］.Journal of Hepatobiliary Surgery，2016，24(3)：196-197.［杨金珠.晚期胆囊癌应用吉西他滨联合替吉奥方案化疗的临床疗效［J］.肝胆外科杂志，2016，24(3)：196-197.］
[15]Quan ZW，Tang CH，Zhuang PY.The effect and safety of new chemotherapy regimen for advanced gallbladder carcinoma：An open multicenter randomized controled trial［J］.Chinese Journal of Hepatobiliary Surgery，2010，16(11)：809-811.［全志伟，汤朝晖，庄鹏远.晚期胆囊癌化疗新方案有效性、安全性的随机、对照、开放、多中心临床研究［J］.中华肝胆外科杂志，2010，16(11)：809-811.］
[16]Bin YH，Cai ZW，Liu HF.Comparison of efficacy and safety of gio combined with oxaliplatin versus fluorouracil combined with cal-cium folinate and oxaliplatin in the treatment of diffuse advanced gastric cancer［J］.China Pharmacy，2016，27(21)：2903-2906.［宾业鸿，蔡正文，刘汉峰.SOX方案与改良mFOLFOX6 方案治疗弥散型进展期胃癌的疗效和安全性比较［J］.中国药房，2016，27(21)：2903-2906.］
[17]Huang DN，Chen SJ，Huang HX，et al.Comparison of SOX and FOLFOX4 regimen in the treatment of advanced gastric cancer［J］.Journal of Basic and Clinical Oncology，2014，27(4)：288-290.［黄东宁，陈绍俊，黄海欣，等.SOX与FOLFOX4方案治疗晚期胃癌的临床对照研究［J］.肿瘤基础与临床，2014，27(4)：288-290.］
[18]Mamo A，Easaw J，Ibnshamsah F，et al.Retrospective analysis of the effect of CAPOX and mFOLFOX6 dose intensity on survival in colorectal patients in the adjuvant setting［J］.Curr Oncol，2016，23(3)：171-177.
[19]Yamazaki K，Nagase M，Tamagawa H，et al.Randomized phase Ⅲ study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer(WJOG4407G)［J］.Ann Oncol，2016，27(8)：1539-1546.

备注/Memo

备注/Memo:

National Natural Science Foundation of China(No.81172362）；国家自然科学基金（编号：81172362）；陕西省教育科学“十二五”规划课题（编号：SGH13513）；陕西省科技统筹创新工程计划项目（编号：2013KTCQ03-08）

常用功能

更新日期/Last Update: 2019-05-31